Liver Fibrosis Drug

Global Liver Fibrosis Drug Market: Global Market Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025

Report ID: BMRC 489 | Number of pages: 204 | Publish Date: Jul 2019 | Category: Lifesciences and Healthcare
Liver Fibrosis Drug Market is valued at USD 12.2 Billion in 2018 and expected to reach USD 22.0 Billion By 2025 with the CAGR of 8.7% over the forecast period. Increased prevalence of liver disorders and favorable reimbursement policies is likely to grow the liver fibrosis drug market.

Scope of Liver Fibrosis Drug Market Report:

Liver fibrosis is a condition of scarring of healthy liver tissue which affects the functioning of those cells. It is the first stage of liver fibrosis, once the liver is scarred it won’t heal or regenerate medications and lifestyle will only keep the condition stable. There are various symptoms which can be observed in the patients such as appetite loss, nausea, weakness, jaundice and others. Most of the people come to know about liver fibrosis in late stages because the symptoms cannot be seen in early stages. There are various types of liver disorders which can cause inflammation in the liver cell and healing led to the formation of scarred tissue during this excess of collagen and proteins build up in liver. Medications are available but permanent cure is not available except liver transplant which cannot be applicable on every patient. Liver Fibrosis Drug Market report is segmented on drug class, distribution channel, and by regional & country level. Based upon drug class, liver fibrosis drug market is segmented into nucleoside analogue, interferon (IFN) therapy, maloti lipid, and others. Based upon distribution channel, liver fibrosis drug market is classified into retail pharmacies, hospital pharmacies and online pharmacies. The regions covered in this Liver Fibrosis Drug market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Liver Fibrosis Drug market is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc. Key Players for Liver Fibrosis Drug Market Reports– Some major key players for Liver Fibrosis Drug market Celgene Corporation, Bristol-Myers Squibb Company, LG Life Science Ltd., FibroGen, Inc., Pharmaxis Limited, Pfizer, Inc., Dicerna Pharmaceuticals, Inc., Gilead Sciences, Inc., and Dynavax Technologies Corporation among others. Increased prevalence of liver disorders and favorable reimbursement policies is the key factor which helps Liver Fibrosis Drug Market to grow. Over the period of time there has been a constant change in the lifestyle and food habits among population which has increased the prevalence of liver disorders over the forecast period. Increase in various major disorders led to the long medication which can also led to the liver fibrosis which in turn expected to promote the liver fibrosis drug market in the near future. Furthermore, favorable reimbursement scenario from various government and non government organizations which are also expected to anticipate the growth of liver fibrosis drug market. Moreover, further development in healthcare services and increase in disposable income is also expected to support the growth of liver fibrosis drug market. Increase in research and development coupled with increase in technological advancement are expected to create ample opportunities in the near future. However, lack of awareness and checkup for liver disorders are expected to hamper the growth of liver fibrosis drugs market over the forecast period. Geographically, this report split global into several key Regions, revenue (Million USD) The geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) focusing on key countries in each region. It also covers market drivers, restraints, opportunities, challenges, and key issues in Global Liver Fibrosis Drug Market. Key Benefits for Liver Fibrosis Drug Market Reports • Global market report covers in-depth historical and forecast analysis. • Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level. • Global market report helps to identify opportunities in market place. • Global market report covers extensive analysis of emerging trends and competitive landscape.

Liver Fibrosis Drug Market Segmentation –

By Drug Class • Nucleoside Analogue • Interferon (Ifn) Therapy • Maloti Lipid • Others By Distribution Channel • Retail Pharmacies • Hospital Pharmacies • Online Pharmacies By Region • North America o U.S. o Canada o Mexico • Europe o UK o France o Germany o Russia o Rest of Europe • Asia-Pacific o China o South Korea o India o Japan o Rest of Asia-Pacific • LAMEA o Latin America o Middle East o Africa North America is expected to dominate the Liver Fibrosis Drug Market. North America is expected to account for the major market share over the forecast period owing to the presence of developed economies such as U.S., Canada and others. The presence of developed healthcare infrastructure coupled with increased awareness about liver disorders and changing lifestyle are expected to promote the growth of liver fibrosis drug market. Europe is expected to account for the second largest market share due to the increase in research and development activities coupled with technological advancement is also expected to promote the growth of liver fibrosis drug market. Asia Pacific is expected to develop significantly owing to the presence of developing economies such as India, China and others. The increased prevalence of liver disorders coupled with favorable reimbursement scenario with changing lifestyle such as food habits, increased consumption of alcohol and smoking and others. Africa, Latin America and Middle East is expected to develop at a considerable rate over the forecast period. Liver Fibrosis Drug Market Key Players: • Gilead • Biogen Idec • Merck KGaA • Bristol-Myers Squibb Company • Roche • Merck & Co. • Tri-Prime others This comprehensive report will provide: • Enhance your strategic decision making • Assist with your research, presentations and business plans • Show which emerging market opportunities to focus on • Increase your industry knowledge • Keep you up-to-date with crucial market developments • Allow you to develop informed growth strategies • Build your technical insight • Illustrate trends to exploit • Strengthen your analysis of competitors • Provide risk analysis, helping you avoid the pitfalls other companies could make • Ultimately, help you to maximize profitability for your company. Our Market Research Solution Provides You Answer to Below Mentioned Question: • Which are the driving factors responsible for the growth of market? • Which are the roadblock factors of this market? • What are the new opportunities, by which market will grow in coming years? • What are the trends of this market? • Which are main factors responsible for new product launch? • How big is the global & regional market in terms of revenue, sales and production? • How far will the market grow in forecast period in terms of revenue, sales and production? • Which region is dominating the global market and what are the market shares of each region in the overall market in 2017? • How will each segment grow over the forecast period and how much revenue will these segment account for in 2025? • Which region has more opportunities?
Interested in this report?
Get your sample now!
Table of Content

1. Chapter - Report Methodology
1.1. Research Process 
1.2. Primary Research 
1.3. Secondary Research
1.4. Market Size Estimates
1.5. Data Triangulation
1.6. Forecast Model 
1.7. USP’s of Report 
1.8. Report Description 
2. Chapter – Global Liver Fibrosis Drug Market Overview: Qualitative Analysis
2.1. Market Introduction
2.2. Executive Summary 
2.3. Global Liver Fibrosis Drug Market Classification
2.4. Market Drivers
2.5. Market Restraints
2.6. Market Opportunity
2.7. Liver Fibrosis Drug Market: Trends
2.8. Porter’s Five Forces Analysis
2.8.1. Bargaining Power of Suppliers
2.8.2. Bargaining Power of Consumers
2.8.3. Threat of New Entrants
2.8.4. Threat of Substitute Product and Services
2.8.5. Competitive Rivalry within the Industry
2.9. Market Attractiveness Analysis 
2.9.1. Market Attractiveness Analysis by Segmentation 
2.9.2. Market Attractiveness Analysis by Region 
3. Chapter - Global Liver Fibrosis Drug Market Overview: Quantitative Analysis
3.1. Global Liver Fibrosis Drug Market Revenue (USD Million), Market Share (%) and Growth Rate (%), 2014- 2025
3.2. Global Liver Fibrosis Drug Market Revenue Market Share (%), 2014- 2025
3.3. Global Liver Fibrosis Drug Market Sales (Number of Units), Market Share (%) and Growth Rate (%), 2014- 2025
3.4. Global Liver Fibrosis Drug Market Sales Market Share (%), 2014- 2025
4. Chapter – Global Liver Fibrosis Drug Market Analysis: By Type
5. Chapter – Global Liver Fibrosis Drug Market Analysis: By Application  
6. Chapter – Global Liver Fibrosis Drug Market Analysis: By End-User
7. Chapter - Global Liver Fibrosis Drug Market Analysis: By Manufacturer
7.1. Global Liver Fibrosis Drug Market Revenue (USD Million), by Manufacturer, 2014 - 2025
7.2. Global Liver Fibrosis Drug Market Share (%), by Manufacturer, 2018
7.3. Global Liver Fibrosis Drug Market Sales (Number of Units), by Manufacturer, 2014 - 2025
7.4. Global Liver Fibrosis Drug Market Share (%), by Manufacturer, 2018
7.5. Global Liver Fibrosis Drug Market Price (USD/Unit), by Manufacturer, 2014 - 2025
7.6. Global Liver Fibrosis Drug Market Revenue Growth Rate (%), by Manufacturer, 2014 – 2025
7.7. Merger & Acquisition
7.8. Collaborations and Partnership
7.9. New Product Launch
8. Chapter –Liver Fibrosis Drug Market: Regional Analysis
8.1. North America
8.1.1. North America Liver Fibrosis Drug Market Revenue (USD Million) and Growth Rate (%), 2014 – 2025.
8.1.2. North America Liver Fibrosis Drug Market Revenue (USD Million) By Country, 2014 – 2025.
8.1.3. North America Liver Fibrosis Drug Revenue Market Share (%) By Country, 2014 – 2025.
8.1.4. North America Liver Fibrosis Drug Market Revenue (USD Million) and Growth Rate, By Market Segmentation, 2014 – 2025.
8.1.5. North America Liver Fibrosis Drug Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2014 – 2025.
8.1.6. North America Liver Fibrosis Drug Market Sales (Number of Units) and Growth Rate (%), 2014 – 2025.
8.1.7. North America Liver Fibrosis Drug Market Sales (Number of Units) By Country, 2014 – 2025.
8.1.8. North America Liver Fibrosis Drug Sales Market Share (%) By Country, 2014 – 2025.
8.1.9. North America Liver Fibrosis Drug Market Sales (Number of Units) and Growth Rate, By Market Segmentation, 2014 – 2025.
8.1.10. North America Liver Fibrosis Drug Market Sales (Number of Units), Market Share (%) and Growth Rate, By Market Segmentation, 2014 – 2025.
8.2. Europe
8.3. Asia Pacific
8.4. Latin America
8.5. Middle East & Africa
9. Chapter - Company Profiles
9.1. Gilead
9.1.1. Financials
9.1.2. Product portfolio
9.1.3. Liver Fibrosis Drug Market Revenue (USD Million) and Market Share (%), 2014 - 2018
9.1.4. Liver Fibrosis Drug Sales Market Share (%), 2014 - 2018
9.1.5. Business strategy
9.1.6. Recent developments
9.2. Gilead
9.3. Biogen Idec
9.4. Merck KGaA
9.5. Bristol-Myers Squibb Company
9.6. Roche
9.7. Merck & Co.
9.8. Tri-Prime
9.9. Others
10. Chapter – Market Research and Findings